ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting

Abstract

We found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.